Loading...
Compass Ratings
The Alexandria Compass
1,005+ stocks rated across NYSE & NASDAQ. Every stock scored 1–100 blending quantitative financials with qualitative moat, catalyst, and theme analysis — updated daily.
Theme Navigation
Browse Alexandria's ratings universe through its major market themes.
Coverage Universe
1,005 rated stocks organized through the Compass framework.
Updated daily
| Logo | Tier | Category | ||||||
|---|---|---|---|---|---|---|---|---|
 | LLY | Eli Lilly and Company | 91 | True North | Biotech & Genomics | $1.1T | +32.0% | 43.0x |
U | URGN | UroGen Pharma Ltd. | 90 | True North | Biotech & Genomics | $2B | +151.6% | - |
T | TGTX | TG Therapeutics, Inc. | 90 | True North | Biotech & Genomics | $8B | +70.3% | 18.9x |
 | DXCM | DexCom Inc. | 90 | True North | Biotech & Genomics | $34B | +20.0% | 35.5x |
S | SEPN | Septerna, Inc. | 89 | True North | Biotech & Genomics | $2B | +12011.0% | - |
 | REGN | Regeneron Pharmaceuticals | 88 | True North | Biotech & Genomics | $87B | +7.0% | 20.8x |
 | ALNY | Alnylam Pharmaceuticals | 88 | True North | Biotech & Genomics | $32B | +40.0% | 42.3x |
H | HRMY | Harmony Biosciences Holdings, Inc. | 88 | True North | Biotech & Genomics | $2B | +30.3% | 12.9x |
 | VRTX | Vertex Pharmaceuticals | 87 | True North | Biotech & Genomics | $140B | +12.0% | 32.2x |
I | IOVA | Iovance Biotherapeutics, Inc. | 87 | True North | Biotech & Genomics | $4B | +65.7% | - |
 | BEAM | Beam Therapeutics | 87 | True North | Biotech & Genomics | $3B | 0.0% | - |
 | CRSP | CRISPR Therapeutics | 86 | True North | Biotech & Genomics | $6B | +68.6% | - |
C | CAI | Caris Life Sciences, Inc. | 86 | True North | Biotech & Genomics | $6B | +78.8% | 2.4x |
D | DNTH | Dianthus Therapeutics, Inc. | 86 | True North | Biotech & Genomics | $6B | +294.3% | - |
O | OSCR | Oscar Health, Inc. | 85 | True North | Biotech & Genomics | $10B | +52.6% | 24.8x |
I | IBRX | ImmunityBio, Inc. | 85 | True North | Biotech & Genomics | $9B | +167.6% | - |
K | KNSA | Kiniksa Pharmaceuticals International, plc | 84 | True North | Biotech & Genomics | $6B | +55.5% | 81.6x |
N | NUVB | Nuvation Bio Inc. | 84 | True North | Biotech & Genomics | $2B | +2598.7% | - |
A | AGIO | Agios Pharmaceuticals, Inc. | 84 | True North | Biotech & Genomics | $2B | +259.3% | - |
 | SYK | Stryker Corporation | 84 | True North | Biotech & Genomics | $130B | +10.0% | 35.3x |
T | TARS | Tarsus Pharmaceuticals, Inc. | 83 | True North | Biotech & Genomics | $3B | +106.9% | - |
L | LQDA | Liquidia Corporation | 83 | True North | Biotech & Genomics | $7B | +4158.5% | 53.8x |
L | LEGN | Legend Biotech Corporation | 83 | True North | Biotech & Genomics | $4B | +56.5% | - |
S | SLN | Silence Therapeutics plc | 82 | True North | Biotech & Genomics | $846M | +197.2% | - |
F | FDMT | 4D Molecular Therapeutics, Inc. | 82 | True North | Biotech & Genomics | $926M | +21664.3% | - |
C | CRON | Cronos Group Inc. | 82 | True North | Biotech & Genomics | $1B | +40.1% | 17.3x |
A | ABUS | Arbutus Biopharma Corporation | 82 | True North | Biotech & Genomics | $985M | +10054.5% | 6.3x |
P | PRLD | Prelude Therapeutics Incorporated | 82 | True North | Biotech & Genomics | $461M | +116.7% | - |
C | CARL | Carlsmed, Inc. | 82 | True North | Biotech & Genomics | $424M | +58.2% | - |
S | SRTA | Strata Critical Medical, Inc. | 82 | True North | Biotech & Genomics | $521M | +87.4% | - |
O | OABI | OmniAb, Inc. | 82 | True North | Biotech & Genomics | $447M | +247.3% | - |
 | RXRX | Recursion Pharmaceuticals | 82 | True North | Biotech & Genomics | $2B | +55.0% | - |
P | PRTC | PureTech Health plc | 82 | True North | Biotech & Genomics | $424M | -38.2% | 9.2x |
Z | ZVRA | Zevra Therapeutics, Inc. | 82 | True North | Biotech & Genomics | $720M | +77.5% | 13.0x |
K | KMTS | Kestra Medical Technologies, Ltd. | 82 | True North | Biotech & Genomics | $2B | +62.7% | - |
L | LXRX | Lexicon Pharmaceuticals, Inc. | 82 | True North | Biotech & Genomics | $1B | +1572.1% | - |
V | VSTM | Verastem, Inc. | 82 | True North | Biotech & Genomics | $661M | +1775.4% | - |
A | ANL | Adlai Nortye Ltd. | 82 | True North | Biotech & Genomics | $923M | +178.1% | - |
A | AGEN | Agenus Inc. | 82 | True North | Biotech & Genomics | $372M | +40.2% | 2.8x |
G | GLPG | Lakefront Biotherapeutics NV | 82 | True North | Biotech & Genomics | $2B | -91.4% | 3.2x |
B | BBNX | Beta Bionics, Inc. | 82 | True North | Biotech & Genomics | $900M | +56.6% | - |
A | AMN | AMN Healthcare Services, Inc. | 82 | True North | Biotech & Genomics | $1B | +99.9% | 13.1x |
A | AKTS | Aktis Oncology, Inc. | 82 | True North | Biotech & Genomics | $1B | +123.0% | - |
A | ASTH | Astrana Health, Inc. | 82 | True North | Biotech & Genomics | $2B | +48.5% | 48.0x |
S | SNDA | Sonida Senior Living, Inc. | 82 | True North | Biotech & Genomics | $2B | +137.1% | - |
I | IRWD | Ironwood Pharmaceuticals, Inc. | 82 | True North | Biotech & Genomics | $720M | +158.9% | 5.5x |
C | CRMD | CorMedix Inc. | 82 | True North | Biotech & Genomics | $664M | +226.1% | 3.9x |
A | ARVN | Arvinas, Inc. | 82 | True North | Biotech & Genomics | $625M | +1014.7% | 37.2x |
P | PRE | Prenetics Global Limited | 82 | True North | Biotech & Genomics | $315M | +210.7% | - |
P | PHAT | Phathom Pharmaceuticals, Inc. | 81 | True North | Biotech & Genomics | $754M | +104.4% | - |